Beta-glucan contamination of pharmaceutical products: How much should we accept? - Wikidata - wikimedia - TriplyDB

Beta-glucan contamination of pharmaceutical products: How much should we accept?

Beta-glucan contamination of pharmaceutical products: How much should we accept?

http://www.wikidata.org/entity/Q28077957

about

Development of downstream processing to minimize beta-glucan impurities in GMP-manufactured therapeutic antibodies.

P2860

Q40528215-A19AC1A5-9B0E-4196-B691-B7647F0BA942

P2860

Beta-glucan contamination of pharmaceutical products: How much should we accept?

http://www.wikidata.org/entity/Q28077957

description

2016 nî lūn-bûn

@nan

2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Beta-glucan contamination of pharmaceutical products: How much should we accept?

@ast

Beta-glucan contamination of pharmaceutical products: How much should we accept?

@en

Beta-glucan contamination of pharmaceutical products: How much should we accept?

@nl

type

label

Beta-glucan contamination of pharmaceutical products: How much should we accept?

@ast

Beta-glucan contamination of pharmaceutical products: How much should we accept?

@en

Beta-glucan contamination of pharmaceutical products: How much should we accept?

@nl

prefLabel

Beta-glucan contamination of pharmaceutical products: How much should we accept?

@ast

Beta-glucan contamination of pharmaceutical products: How much should we accept?

@en

Beta-glucan contamination of pharmaceutical products: How much should we accept?

@nl

P1433

Q28077957-DA4A2FF7-11F0-432D-84B5-F5846DE7EBE8

P1476

Q28077957-E6A7B26A-C3F9-4594-A9EC-5794720EC77A

P2093

Q28077957-036F92E9-10F5-4586-8584-119C1190DF8C

Q28077957-6822471E-5A0E-42D6-9F83-8C8A1E607E13

Q28077957-7D4A09D9-30BE-46D5-9C95-67E1FA3B42C7

Q28077957-92ADF208-4AED-4277-843E-2EA028831288

Q28077957-C70CA938-2B16-4D45-84A2-B0C3F92AD6A5

Q28077957-FDF8879F-A385-4DFE-A678-0E9F6D84D1FC

P275

Q28077957-D5D35960-3709-486C-8031-88FE0BC062F7

P2860

Q28077957-00A4D708-50D0-4567-B2DF-D8F34AEF7D3E

Q28077957-0190F76D-77A9-49EA-A209-F9AB0CEA998B

Q28077957-0D9AE994-6454-40BE-A3E6-9E2036C26041

Q28077957-11D1B194-86BE-477F-86D9-310F7A8A4376

Q28077957-16D8F91C-7BC8-4BE2-BA77-55EE4B8483C2

Q28077957-184E3B59-575E-4202-8DF6-ECA4A9AE6EED

Q28077957-198E2BC9-5978-4815-9C3A-35EEFBA9C26A

Q28077957-211D5471-5E24-4873-8464-17AD1DC365EC

Q28077957-2329837F-6691-47C6-B357-452E7C6BB5F4

Q28077957-27C36179-6217-4EDC-8495-48924B9A2186

P2888

Q28077957-C242DE11-1E73-4DD5-94F9-2C0E6F11F567

P304

Q28077957-46A387FF-C749-4DCF-8C4D-48313C3E108D

P31

Q28077957-B2B3EC8B-8AB3-46AB-9CA5-92C5F2BD6BA9

P3181

Q28077957-F49986A9-B97F-4434-94AE-C9E0EDDDA868

P356

Q28077957-466CDD15-1912-431B-BFD8-85D38EF33ADF

P407

Q28077957-660A99B1-E6E7-466B-9F09-891E56516B76

P433

Q28077957-454A8972-9A3D-4185-B01C-1C3AD63572D8

P478

Q28077957-CF8DD1CD-24EC-4FBD-BFC8-809C12384056

P50

Q28077957-85A174FB-C91E-44D5-97D3-9D8678E1ED90

Q28077957-9EFF937F-C335-470E-BF7E-24281AEC2B59

Q28077957-DB359712-5432-4D15-AA2E-9AF48EA9A6BC

P5008

Q28077957-94A6C4FA-970B-4420-8F65-4BF600741F57

P577

Q28077957-163F4488-6DF3-43C1-A192-FC076169F143

P6179

Q28077957-68C30254-F88A-41AA-AA8C-7BDE0648FC46

P698

Q28077957-6DDF40C7-7B8E-4E7E-8922-447E7477AAC6

P921

Q28077957-0365CB5B-5A63-46D9-891A-ECA82E5A18F5

Q28077957-0AE5E199-6877-4AF4-A688-09A7C4FEB0D5

Q28077957-24D651E3-712F-49F1-A14E-49BB0FB8AB1A

Q28077957-57BDCF4D-1036-48D0-BB38-04D6276DEF05

Q28077957-CBAECA19-222E-4C65-97B5-896D38413121

P932

Q28077957-E7FD90D8-65DE-4087-9929-864CF6F52BB5

P3181

P356

S00262-016-1875-9

P1433

Cancer Immunology, Immunotherapy

P1476

Beta-glucan contamination of pharmaceutical products: How much should we accept?

@en

P2093

Debra H Josephs

http://www.w3.org/2001/XMLSchema#string

Heather J Bax

http://www.w3.org/2001/XMLSchema#string

Heike Lentfer

http://www.w3.org/2001/XMLSchema#string

Kim Vigor

http://www.w3.org/2001/XMLSchema#string

Paul Jones

http://www.w3.org/2001/XMLSchema#string

Robert Scott

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy

β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3)

Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer

Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome

A placebo-controlled trial of the immune modulator, lentinan, in HIV-positive patients: a phase I/II trial.

Isolation, physicochemical characterization and preclinical efficacy evaluation of soluble scleroglucan.

Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastoma

Cholesterol-lowering effects of oat β-glucan: a meta-analysis of randomized controlled trials.

Induction of tumoricidal activity of polymorphonuclear leukocytes by a linear beta-1,3-D-glucan and other immunomodulators in murine cells.

Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells.

P2888

s00262-016-1875-9

P304

1289-1301

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4238960

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S00262-016-1875-9

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P50

Sophia N. Karagiannis

P5008

P577

2016-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1018321762

http://www.w3.org/2001/XMLSchema#string

P698

27473075

http://www.w3.org/2001/XMLSchema#string

P921

Angliavandeniai

pharmaceutical preparation

biomedical investigative technique

P932

5069311

http://www.w3.org/2001/XMLSchema#string